Background: Mirabegron is a �²3-adrenoreceptor agonist developed for treatment of overactive bladder (OAB).\n�±1-Adrenergic receptor blockers are effective for lower urinary tract symptoms (LUTS) in male patients. However,\nthe efficacy of mirabegron additional treatment in elderly male patients with persistent male LUTS, especially in\nOAB after monotherapy with �±1-adrenergic blockers, is not fully understood.\nMethods: This study was conducted in male LUTS patients who were â�¥ 65 years of age and had persistent OAB\nsymptoms, regardless of whether they took an �±1-adrenergic receptor blocker orally. Before and 12 weeks after\nmirabegron additional therapy (50 mg once daily), we evaluated the efficacy of this treatment using the Overactive\nBladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS), and changes in the maximum\nflow rate (Qmax) and post-void residual urine volume (PVR). We evaluated patients overall and divided into two\ngroups by age: young-old (from 65 to 74 years old) and old-old (from 75 to 84 years old).\nResults: Fifty men were enrolled in this study. Mirabegron additional therapy improved the total OABSS, total IPSS,\nand IPSS-quality of life (QOL) score. The voided volume (VV) and Qmax improved after treatment in patients overall.\nHowever, there was no significant change in PVR. The total OABSS, total IPSS, and IPSS-QOL score significantly\nimproved in both of the young-old and old-old groups. However, a significant increasing of VV was detected in the\nyoung-old group. There were no significant differences in the Qmax or PVR in either group.\nConclusions: Mirabegron additional therapy was effective for male patients whose persistent LUTS and particularly\nOAB was not controlled with �±1-adrenergic receptor blocker monotherapy, and mirabegron did not have negative\neffects on voiding function. Additionally, mirabegron additional therapy was considered effective regardless of\npatient age.
Loading....